Kite Pharma Competitors and Similar CompaniesClear all
Kite Pharma's competitors and similar companies include G1 Therapeutics, Achilles Therapeutics, Novartis and Juno Therapeutics.
 G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Juno Therapeutics Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer. | ||
Founding Date | Founding Date 2009 | Founding Date 2008 | Founding Date 2016 | Founding Date 1996 | Founding Date 2013 |
Type | Type Subsidiary | Type Public | Type Private | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Santa Monica, US HQ Hoofddorp, NL London, GB El Segundo, US Emeryville, US Frederick, US Oceanside, US see more | Locations Durham, US HQ | Locations London, GB HQ Stevenage, GB | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Seattle, US HQ Göttingen, DE Göttingen, DE München, DE München, DE Bothell, US Brisbane, US |
Employees | Employees 3,9671% decrease | Employees 17015% increase | Employees 695% decrease | Employees 75,883 | Employees 1091% decrease |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $111.9m (FY, 2017) |
Cost of goods | Cost of goods N/A | Cost of goods $7.2m (FY, 2023) | Cost of goods N/A | Cost of goods $8.4b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $75.3m (FY, 2023) | Gross profit N/A | Gross profit $49.8b (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($48m) (FY, 2023) | Net income ($69.7m) (FY, 2023) | Net income $14b (FY, 2025) | Net income ($437.1m) (FY, 2017) |
Operating ⚠ | |||||
Patents (US) | Patents (US) N/A | Patents (US) 40 (FY, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) 72 (FY, 2016) |
Trademarks (US) | Trademarks (US) 19 (Jan, 2024) | Trademarks (US) N/A | Trademarks (US) 3 (May, 2021) | Trademarks (US) N/A | Trademarks (US) N/A |
Funding | |||||
Total funding raised | Total funding raised $ 85.3m | Total funding raised $ 289.6m | Total funding raised $ 138.1m | Total funding raised $ 6.5m | Total funding raised $ 310m |
For sources of this data, please see the company profile
View Company Profiles
G1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View companyAchilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyJuno Therapeutics
HQ
Seattle, US
Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer.
View company